platoseedplatoseed
Converting biology into digital molecular maps
Finding new cures requires seeing what and where the abnormal molecules are in a diseased tissue, but current tools see less than 1% of those molecules. Biocartesian combines microscopy and new chemistries to see 50X more, offering unprecedented insights into disease biology and new therapies.
Co-founder of Biocartesian. Microscopy + molecular tools + engineering. Previously Bioscience Enterprise at Cambridge, Bioengineering PhD at UPenn.
Co-founder of Biocartesian. Genetics + epigenetics, next-gen sequencing. Previously PhD at UPenn, BD at imvaria.
We use chemistry and microscopy to help scientists discover new drugs.
Biocartesian combines new chemistries and microscopy to map molecules in biological specimens, enabling researchers to see more of the molecular landscape and accelerate drug discovery. The launch presents a service that converts specimens into digital molecular maps to speed data collection, reduce costs, and broaden access to bespoke assays for scientists across disease areas.
Formerly “coordna bio” · why startups rename →
AI Hypothesis Engine for Molecular Discovery
Using the immune system to cure disease
